跳到主要导航
跳到搜索
跳到主要内容
北京成人头条 首页
English
中文
首页
师资队伍
研究单位
科研成果
奖项
按专业知识、名称或附属进行搜索
查看 Scopus 资料
吕 芳
生命学院
h-index
1268
引用
20
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
2010
2025
每年的科研成果
概览
指纹图谱
合作网络
科研成果
(92)
相似学者
(2)
个人简介
指纹图谱
深入其中 Fang Lv 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
2
相似简介
Randomized Controlled Trial
Pharmacology, Toxicology and Pharmaceutical Science
100%
Osteogenesis Imperfecta
Pharmacology, Toxicology and Pharmaceutical Science
97%
Bone Development
Biochemistry, Genetics and Molecular Biology
79%
Non Insulin Dependent Diabetes Mellitus
Pharmacology, Toxicology and Pharmaceutical Science
73%
Glucagon Like Peptide 1 Receptor Agonist
Pharmacology, Toxicology and Pharmaceutical Science
73%
Sodium Glucose Cotransporter 2 Inhibitor
Pharmacology, Toxicology and Pharmaceutical Science
73%
Alendronic Acid
Pharmacology, Toxicology and Pharmaceutical Science
65%
FKBP10
Biochemistry, Genetics and Molecular Biology
57%
科研成果
每年的科研成果
2010
2016
2017
2018
2020
2021
2022
2023
2024
2025
2025
80
文章
7
文献综述
2
会议稿件
2
评论/辩论
1
更多
1
快报
每年的科研成果
每年的科研成果
Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models
Zhang, M., Li, Z., Cai, X.,
Lv, F.
, Wen, X., Guo, C., Lin, C. & Ji, L.,
2025
,
在:
International Journal of Medical Sciences.
22
,
13
,
页码 3229-3241
13 页码
科研成果
:
期刊稿件
›
文章
›
同行评审
Liraglutide
100%
ATTR Amyloidosis
100%
Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis
Jiao, R., Lin, C., Cai, X., Wang, J., Wang, Y.,
Lv, F.
, Yang, W. & Ji, L.,
1月 2025
,
在:
Diabetes, Obesity and Metabolism.
27
,
1
,
页码 259-267
9 页码
科研成果
:
期刊稿件
›
文章
›
同行评审
Glucagon-Like Peptide 1 Receptor
100%
Lean Body Weight
20%
Glucagon-Like Peptide-1 Agonist
11%
Gastric Inhibitory Polypeptide
11%
Receptor Agonists
10%
14
引用 (Scopus)
Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity
Wang, J., Lin, C., Cai, X., Wang, Y., Wei, T., Wang, Y., Tie, C., Yang, Y.,
Lv, F.
, Yang, W. & Ji, L.,
9月 2025
,
在:
Diabetes, Obesity and Metabolism.
27
,
9
,
页码 5042-5051
10 页码
科研成果
:
期刊稿件
›
文章
›
同行评审
Body Weight Fluctuation
100%
Glucagon-Like Peptide-1
100%
Serum Creatinine
66%
Semaglutide
60%
Body Fat
40%
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
Zhang, M., Lin, C., Cai, X., Jiao, R., Bai, S., Li, Z.,
Lv, F.
, Yang, W., Liu, G., Yang, X. & Ji, L.,
2月 2025
,
在:
Diabetes, Obesity and Metabolism.
27
,
2
,
页码 806-815
10 页码
科研成果
:
期刊稿件
›
文章
›
同行评审
Combination Therapy
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Monotherapy
100%
Non Insulin Dependent Diabetes Mellitus
33%
5
引用 (Scopus)
Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis of randomized controlled trials
Wang, Y., Li, Z., Lin, C., Zhou, J., Cai, X.,
Lv, F.
, Yang, W. & Ji, L.,
2025
,
在:
Expert Review of Clinical Pharmacology.
18
,
3
,
页码 165-173
9 页码
科研成果
:
期刊稿件
›
文献综述
›
同行评审
Randomized Controlled Trial
100%
Neoplasm
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Non Insulin Dependent Diabetes Mellitus
100%
Systematic Review
100%